FIELD: medicine.
SUBSTANCE: invention relates to medicine. Disclosed is a method for preparing an intermediate compound of an antibody-drug conjugate comprising a linker and a functional fragment of a drug, in which the antibody-drug conjugate intermediate is Py–MAA–Val–Cit–PAB–D, Py–MAA–Val–Cit–PAB is a linker, D is an attachable functional fragment of the drug and the attached functional fragment of the drug contains a free amino group.
EFFECT: invention provides reduced loss of a functional fragment of the drug, id est functional fragment of the drug is used at the last stage of the reaction.
15 cl, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ONE-REACTOR METHOD FOR OBTAINING AN ANTIBODY-DRUG CONJUGATE INTERMEDIATE PRODUCT | 2020 |
|
RU2745738C1 |
| ANTI-MESOTHELIN ANTIBODY AND CONJUGATE THEREOF WITH MEDICINAL PRODUCTS | 2019 |
|
RU2747995C1 |
| LINKER FOR ANTIBODY-DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2792201C2 |
| ANTI-c-MET DRUG CONJUGATE AND USE THEREOF | 2021 |
|
RU2822497C1 |
| ANTIBODY-DRUG CONJUGATE LOADED WITH BINARY TOXINS AND ITS USE | 2021 |
|
RU2795148C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND ITS ANTIBODY-DRUG CONJUGATE | 2022 |
|
RU2814164C2 |
| MATERIALS AND METHODS ASSOCIATED WITH LINKERS FOR USE IN DRUG AND PROTEIN CONJUGATES | 2015 |
|
RU2737553C2 |
| ANTIBODY-DRUG CONJUGATES WITH HIGH DRUG LOADING | 2015 |
|
RU2674979C2 |
| ANTIBODY-DRUG CONJUGATE HAVING AN ACID SELF-STABILIZING BINDING SITE | 2018 |
|
RU2793125C2 |
| ANTIBODIES AGAINST TENB2 CONSTRUCTED WITH CYSTEINE, AND CONJUGATES, ANTIBODY-DRUG | 2008 |
|
RU2505544C2 |
